Date: 2016-11-08
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 4th International mRNA Health Conference
Company: Curevac (Germany)
Product: mRNA-encoded antibodies, RNAntibody® technology.
Action
mechanism: mRNA. RNAntibody® is designed to enable the prolonged expression of functional antibodies and antibody-like proteins from mRNA. It is intended for use as a transient, long lasting and safe passive immunization technology in prophylactic and therapeutic settings.
RNAntibody® technology can be applied in many disease indications including cancer, cardiovascular diseases, infectious diseases and autoimmune diseases.
Disease:
Therapeutic
area:
Country:
Trial
details:
Latest
news:
- • On November 8, 2016, CureVac announced that the company has presented data on its RNAntibody® technology at the 4th International mRNA Health Conference in Boston, MA. In a talk by Dr. Nigel Horscroft, Vice President Development RNArt®, and a poster by Dr. Thomas Schlake, Head of Enabling Technologies, the company demonstrated the utility and flexibility of the technology in multiple disease indications:
- - High and sustained serum levels of antibodies were produced rapidly following a single administration of mRNA in vivo.
- - Substantial levels of mRNA expressed human antibodies persisted for more than 28 days after one dose of in vivo application.
- - In a rabies virus infection model, an mRNA encoded antibody was able to protect 100 percent, not only when administered before the challenge, but also in a post-exposure scenario.
Data was also presented showing protection in two toxin-mediated disease models using mRNA-encoded single domain VHH antibodies.
- In the field of oncology, two approved antibody therapeutics, blinatumomab and rituximab, were adapted to mRNA format and protected animals in relevant tumor challenge models.
Is
general: Yes
